Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis

Authors: Giovanna Mantegna, Marco Petrillo, Gilda Fuoco, Laura Venditti, Serena Terzano, Luigi Pedone Anchora, Giovanni Scambia, Gabriella Ferrandina

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

A long-term prospective assessment of QoL in cervical cancer patients is still lacking. Here, we provide the first 2-years prospective, longitudinal study evaluating emotional distress and QoL in early stage (ECC) and locally advanced (LACC) cervical cancer patients who remained disease-free 2-years from diagnosis.

Methods

The questionnaires: Hospital Anxiety and Depression Scale (HADS), Global Health Status items of EORTC QLQ-C30 (GHS), and EORTC QLQ-CX24 (CX24) have been administered by a dedicated team of psycho-oncologists, administered at baseline, and after 3, 6, 12 and 24 months from surgery The Generalized Linear Model for repeated measure was used to analyze modifications of QoL measures over time.

Results

In both groups, an early reduction of the percentage of patients with anxiety levels ≥11 was observed at the 3-month evaluation (ECC: 25.7% at baseline Vs 14.7% after 3 months, p value=0.001; LACC: 22.2% at baseline Vs 15.4% after 3 months, p value=0.001). Despite this favorable trend, after 2 years from diagnosis, 11.9% of ECC and 15.6% of LACC patients still showed an anxiety score ≥11. No significant changes over time were observed in term of Depression levels. Focusing on QoL issues, mean GHS and Sexual Activity scores showed an improvement over time in both groups compared to baseline (GHS: 5.7% difference for ECC, p value=0.001, and 11.0% in LACC, p value=0.001; SXA: 13.9% difference for ECC, p value=0.001; and 6.1% in LACC, p value=0.008). On the other hand, Body Image mean scores were significantly impaired by chemoradiation administration in LACC patients, without long-term recovery (7.5% difference, p value=0.001). Finally, in both groups, lymphedema (LY) and menopausal symptoms (MS) showed an early worsening which persisted 2-year after surgery (LY: 19.5% difference for ECC, p value=0.014, and 27.3% in LACC, p value=0.001; MS: 14.4% difference for ECC, p value=0.004, and 16.0% in LACC, p value=0.002).

Conclusions

Despite a significant improvement over time, elevated anxiety levels are still detectable at 24 months after surgery in approximately 10% of cervical cancer patients. Much more attention should be focused on surgical/medical approaches able to minimize the negative impact of lymphedema and menopausal symptoms on QoL.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vistad I, Fossa SD, Dahl AA: A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol. 2006, 102: 563-572. 10.1016/j.ygyno.2006.03.050.CrossRefPubMed Vistad I, Fossa SD, Dahl AA: A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol. 2006, 102: 563-572. 10.1016/j.ygyno.2006.03.050.CrossRefPubMed
2.
go back to reference Chase DM, Watanabe T, Monk BJ: Assessment and significance of quality of life in women with gynecologic cancer. Future Oncol. 2010, 6: 1279-1287. 10.2217/fon.10.96.CrossRefPubMed Chase DM, Watanabe T, Monk BJ: Assessment and significance of quality of life in women with gynecologic cancer. Future Oncol. 2010, 6: 1279-1287. 10.2217/fon.10.96.CrossRefPubMed
3.
go back to reference Juraskova I, Butow P, Robertson R, Sharpe L, McLeod C, Hacker N: Post-treatment sexual adjustment following cervical and endometrial cancer: a qualitative insight. Psycho-Oncol. 2003, 12: 267-279. 10.1002/pon.639.CrossRef Juraskova I, Butow P, Robertson R, Sharpe L, McLeod C, Hacker N: Post-treatment sexual adjustment following cervical and endometrial cancer: a qualitative insight. Psycho-Oncol. 2003, 12: 267-279. 10.1002/pon.639.CrossRef
4.
go back to reference Park SY, Bae DS, Nam JH, Park CT, Cho CH, Lee JM, Lee MK, Kim SH, Park SM, Yun YH: Quality of life and sexual problems in cervical cancer survivors. Cancer. 2007, 110: 2716-2725. 10.1002/cncr.23094.CrossRefPubMed Park SY, Bae DS, Nam JH, Park CT, Cho CH, Lee JM, Lee MK, Kim SH, Park SM, Yun YH: Quality of life and sexual problems in cervical cancer survivors. Cancer. 2007, 110: 2716-2725. 10.1002/cncr.23094.CrossRefPubMed
5.
go back to reference Korfage IJ, Essink-Bot ML, Mols F, van de Poll-Franse L, Kruitwagen R, van Ballegooijen M: Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys. 2009, 73: 1501-1509. 10.1016/j.ijrobp.2008.06.1905.CrossRefPubMed Korfage IJ, Essink-Bot ML, Mols F, van de Poll-Franse L, Kruitwagen R, van Ballegooijen M: Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys. 2009, 73: 1501-1509. 10.1016/j.ijrobp.2008.06.1905.CrossRefPubMed
6.
go back to reference Evans DW, McCartney CF, Nemeroff CB, Raft D, Quade D, Golden RN, Haggerty JJ, Holmes V, Simon JS, Droba M: Depression in women treated for gynaecological cancer: clinical and neuroendocrine assessment. Am J Psychiatry. 1986, 143: 447-452.CrossRefPubMed Evans DW, McCartney CF, Nemeroff CB, Raft D, Quade D, Golden RN, Haggerty JJ, Holmes V, Simon JS, Droba M: Depression in women treated for gynaecological cancer: clinical and neuroendocrine assessment. Am J Psychiatry. 1986, 143: 447-452.CrossRefPubMed
7.
go back to reference Cain EN, Kohorn EI, Quinlan DM, Schwartz PE, Latimer K, Rogers L: Psychosocial reactions to the diagnosis of gynecologic cancer. Obstet Gynecol. 1983, 62: 635-641.PubMed Cain EN, Kohorn EI, Quinlan DM, Schwartz PE, Latimer K, Rogers L: Psychosocial reactions to the diagnosis of gynecologic cancer. Obstet Gynecol. 1983, 62: 635-641.PubMed
8.
go back to reference Distefano M, Riccardi S, Capelli G, Costantini B, Petrillo M, Ricci C, Scambia G, Ferrandina G: Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy. Gynecol Oncol. 2008, 111: 144-150.CrossRefPubMed Distefano M, Riccardi S, Capelli G, Costantini B, Petrillo M, Ricci C, Scambia G, Ferrandina G: Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy. Gynecol Oncol. 2008, 111: 144-150.CrossRefPubMed
9.
go back to reference Ferrandina G, Margariti PA, Smaniotto D, Petrillo M, Salerno MG, Fagotti A, Macchia G, Morganti AG, Cellini N, Scambia G: Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol. 2010, 119: 404-410. 10.1016/j.ygyno.2010.08.004.CrossRefPubMed Ferrandina G, Margariti PA, Smaniotto D, Petrillo M, Salerno MG, Fagotti A, Macchia G, Morganti AG, Cellini N, Scambia G: Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol. 2010, 119: 404-410. 10.1016/j.ygyno.2010.08.004.CrossRefPubMed
10.
go back to reference Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC): Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010, CD008285-1 Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC): Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010, CD008285-1
11.
go back to reference Weisman AD, Worden JW: The existential plight in cancer: significance of the first 100 days. Int J Psychiatry Med. 1976, 7: 1-15. 10.2190/UQ2G-UGV1-3PPC-6387.CrossRefPubMed Weisman AD, Worden JW: The existential plight in cancer: significance of the first 100 days. Int J Psychiatry Med. 1976, 7: 1-15. 10.2190/UQ2G-UGV1-3PPC-6387.CrossRefPubMed
12.
go back to reference Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC: Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005, 23: 7428-7436. 10.1200/JCO.2004.00.3996.CrossRefPubMed Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC: Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005, 23: 7428-7436. 10.1200/JCO.2004.00.3996.CrossRefPubMed
13.
go back to reference Greimel ER, Winter R, Kapp KS, Haas J: Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psycho-Oncol. 2009, 18: 476-482. 10.1002/pon.1426.CrossRef Greimel ER, Winter R, Kapp KS, Haas J: Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psycho-Oncol. 2009, 18: 476-482. 10.1002/pon.1426.CrossRef
14.
go back to reference Kobayashi M, Ohno T, Noguchi W, Matsuda A, Matsushima E, Kato S, Tsujii H: Psychological distress and quality of life in cervical cancer survivors after radiotherapy: do treatment modalities, disease stage, and self-esteem influence outcomes?. Int J Gynecol Cancer. 2009, 19: 1264-1268. 10.1111/IGC.0b013e3181a3e124.CrossRefPubMed Kobayashi M, Ohno T, Noguchi W, Matsuda A, Matsushima E, Kato S, Tsujii H: Psychological distress and quality of life in cervical cancer survivors after radiotherapy: do treatment modalities, disease stage, and self-esteem influence outcomes?. Int J Gynecol Cancer. 2009, 19: 1264-1268. 10.1111/IGC.0b013e3181a3e124.CrossRefPubMed
15.
go back to reference Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, Anton-Culver H, Berkowitz R, Aziz N: Quality of life in long-term cervical cancer survivors. Gynecol Oncol. 2005, 97: 310-7. 10.1016/j.ygyno.2005.01.010.CrossRefPubMed Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, Anton-Culver H, Berkowitz R, Aziz N: Quality of life in long-term cervical cancer survivors. Gynecol Oncol. 2005, 97: 310-7. 10.1016/j.ygyno.2005.01.010.CrossRefPubMed
16.
go back to reference Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Moruzzi C, Lorusso D, Marcellusi A, Scambia G: Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol. 2012, 124: 389-394. 10.1016/j.ygyno.2011.09.041.CrossRefPubMed Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Moruzzi C, Lorusso D, Marcellusi A, Scambia G: Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol. 2012, 124: 389-394. 10.1016/j.ygyno.2011.09.041.CrossRefPubMed
17.
go back to reference Ferrandina G, Legge F, Fagotti A, Fanfani F, Distefano M, Morganti A, Cellini N, Scambia G: Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome and prognostic measures. Gynecol Oncol. 2007, 107: S127-S132. 10.1016/j.ygyno.2007.07.006.CrossRefPubMed Ferrandina G, Legge F, Fagotti A, Fanfani F, Distefano M, Morganti A, Cellini N, Scambia G: Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome and prognostic measures. Gynecol Oncol. 2007, 107: S127-S132. 10.1016/j.ygyno.2007.07.006.CrossRefPubMed
18.
go back to reference Legge F, Margariti PA, Lucidi A, Macchia G, Petrillo M, Iannone V, Carone V, Morganti AG, Scambia G, Ferrandina G: Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures. Acta Oncol. 2013, 52: 166-173. 10.3109/0284186X.2012.698753.CrossRefPubMed Legge F, Margariti PA, Lucidi A, Macchia G, Petrillo M, Iannone V, Carone V, Morganti AG, Scambia G, Ferrandina G: Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures. Acta Oncol. 2013, 52: 166-173. 10.3109/0284186X.2012.698753.CrossRefPubMed
19.
go back to reference Ferrandina G, Lucidi A, Paglia A, Corrado G, Macchia G, Tagliaferri L, Fanfani F, Morganti AG, Valentini V, Scambia G: Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: impact on outcome and treatment-related complications. Eur J Surg Oncol. 2012, 38: 238-244. 10.1016/j.ejso.2011.12.001.CrossRefPubMed Ferrandina G, Lucidi A, Paglia A, Corrado G, Macchia G, Tagliaferri L, Fanfani F, Morganti AG, Valentini V, Scambia G: Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: impact on outcome and treatment-related complications. Eur J Surg Oncol. 2012, 38: 238-244. 10.1016/j.ejso.2011.12.001.CrossRefPubMed
20.
go back to reference Zigmond AS, Snaith RP: The Hospital Anxiety and Depression scale. Acta Psychiatr Scand. 1983, 67: 361-370. 10.1111/j.1600-0447.1983.tb09716.x.CrossRefPubMed Zigmond AS, Snaith RP: The Hospital Anxiety and Depression scale. Acta Psychiatr Scand. 1983, 67: 361-370. 10.1111/j.1600-0447.1983.tb09716.x.CrossRefPubMed
21.
go back to reference Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G: Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. 1999, 7: 121-127. 10.1007/s005200050241.CrossRefPubMed Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G: Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. 1999, 7: 121-127. 10.1007/s005200050241.CrossRefPubMed
22.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85: 365-376. 10.1093/jnci/85.5.365.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85: 365-376. 10.1093/jnci/85.5.365.CrossRefPubMed
23.
go back to reference Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, Singer S, Chie W, Nordin A, Bjelic Radisic V, Wydra D, European Organization for Research and Treatment of Cancer Quality-of-Life Group: The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer. 2006, 107: 1812-1822. 10.1002/cncr.22217.CrossRefPubMed Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, Singer S, Chie W, Nordin A, Bjelic Radisic V, Wydra D, European Organization for Research and Treatment of Cancer Quality-of-Life Group: The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer. 2006, 107: 1812-1822. 10.1002/cncr.22217.CrossRefPubMed
24.
go back to reference Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM: Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core. J Clin Oncol. 2011, 29: 89-96. 10.1200/JCO.2010.28.0107.CrossRefPubMed Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM: Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core. J Clin Oncol. 2011, 29: 89-96. 10.1200/JCO.2010.28.0107.CrossRefPubMed
25.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998, 16: 139-144.PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998, 16: 139-144.PubMed
26.
go back to reference Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA: Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007, 110: 196-202. 10.1002/cncr.22799.CrossRefPubMed Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA: Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007, 110: 196-202. 10.1002/cncr.22799.CrossRefPubMed
27.
go back to reference Lutgendorf SK, Anderson B, Ullrich P, Johnsen EL, Buller RE, Sood AK, Sorosky JI, Ritchie J: Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer. 2002, 94: 131-140. 10.1002/cncr.10155.CrossRefPubMed Lutgendorf SK, Anderson B, Ullrich P, Johnsen EL, Buller RE, Sood AK, Sorosky JI, Ritchie J: Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer. 2002, 94: 131-140. 10.1002/cncr.10155.CrossRefPubMed
28.
go back to reference Petersen RW, Quinlivan JA: Preventing anxiety and depression in gynaecological cancer: a randomised controlled trial. BJOG. 2002, 109: 386-394. 10.1111/j.1471-0528.2002.01271.x.CrossRefPubMed Petersen RW, Quinlivan JA: Preventing anxiety and depression in gynaecological cancer: a randomised controlled trial. BJOG. 2002, 109: 386-394. 10.1111/j.1471-0528.2002.01271.x.CrossRefPubMed
29.
go back to reference Suzuki N, Ninomiya M, Maruta S, Hosonuma S, Nishigaya Y, Kobayashi Y, Kiguchi K, Ishizuka B: Psychological characteristics of Japanese gynecologic cancer patients after learning the diagnosis according to the hospital anxiety and depression scale. J Obstet Gynaecol Res. 2011, 37: 800-808. 10.1111/j.1447-0756.2010.01437.x.CrossRefPubMed Suzuki N, Ninomiya M, Maruta S, Hosonuma S, Nishigaya Y, Kobayashi Y, Kiguchi K, Ishizuka B: Psychological characteristics of Japanese gynecologic cancer patients after learning the diagnosis according to the hospital anxiety and depression scale. J Obstet Gynaecol Res. 2011, 37: 800-808. 10.1111/j.1447-0756.2010.01437.x.CrossRefPubMed
30.
go back to reference Andersen BL, Farrar WB, Golden-Kreutz D, Emery CF, Glaser R, Crespin T, Carson WE: Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun. 2007, 21: 953-961. 10.1016/j.bbi.2007.03.005.CrossRefPubMedPubMedCentral Andersen BL, Farrar WB, Golden-Kreutz D, Emery CF, Glaser R, Crespin T, Carson WE: Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun. 2007, 21: 953-961. 10.1016/j.bbi.2007.03.005.CrossRefPubMedPubMedCentral
31.
go back to reference Dursun P, Ayhan A, Kuscu E: Nerve-sparing radical hysterectomy for cervical carcinoma. Crit Rev Oncol Hematol. 2009, 70: 195-205. 10.1016/j.critrevonc.2008.09.003.CrossRefPubMed Dursun P, Ayhan A, Kuscu E: Nerve-sparing radical hysterectomy for cervical carcinoma. Crit Rev Oncol Hematol. 2009, 70: 195-205. 10.1016/j.critrevonc.2008.09.003.CrossRefPubMed
Metadata
Title
Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis
Authors
Giovanna Mantegna
Marco Petrillo
Gilda Fuoco
Laura Venditti
Serena Terzano
Luigi Pedone Anchora
Giovanni Scambia
Gabriella Ferrandina
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-127

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine